4Lars sandfelde, David MB, Rbert G. Blood loss duringTransurethral resection of the prostate after 3 months of treatment with finastolide [J]. Urology,2001,58:972 -976.
4[1]Tubaro A, Carter S, Hind A, et al. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol, 2001,166:172-176.
5Carlin BI, Boder DR, Spirnak JP, et al. Role of finasteride in the treatment of recurrent heamaturia secondary to benign prostatic hyperplasia. Prostate, 1997,31 : 180-182.
6Foley SJ,Soloman LZ, Wedderburn AW .et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Uro1,2000,163:436-438.
7Vemeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumors:an international consensus on the methodology and criteria of evaluation. Eur J Cancer, 1996,32A : 2474-2484.
8Hahn RG. Dextran 70 and blood loss during transurethral resection of the prostate. Acta Anaes Scand, 1996,40 ;820-823.
9Lekas JM, Widmark BA, Damber JE. Decrement of blood flow preceeds the involution of the ventral prostate in the rat after castration.Urol Res, 1997,25:309-314.
10Takeshita S, Lu Hang, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest, 1994,93:662-665.
